東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Do newer prescription drugs pay for ...

Zhang, Yuting.

FindBook

Google Book

Amazon

博客來

Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies./
作者:	Zhang, Yuting.
面頁冊數:	101 p.
附註:	Adviser: Richard G. Frank.
Contained By:	Dissertation Abstracts International68-05A.
標題:	Economics, General. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3265137
ISBN:	9780549038405

Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies.
Zhang, Yuting.

Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies. - 101 p.

Adviser: Richard G. Frank.

Thesis (Ph.D.)--Harvard University, 2007.

Newer and more expensive drugs account for a large proportion of the recent rapid growth of prescription drug spending. However, if use of newer drugs can reduce spending on other medical services, it may save total healthcare costs (the "cost-saving effect"). Aggregate-level evidence of the cost-saving effect is supported by two well-cited studies conducted by Frank Lichtenberg. He argued that in the aggregate, using new drugs reduces total healthcare costs. In Paper 1, I reassess this evidence and conclude the original findings are not maintained under plausible alternative approaches. Thus, we do not have robust evidence of the aggregate cost-saving effect.

ISBN: 9780549038405Subjects--Topical Terms:

1017424
Economics, General.

Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies.
LDR:03410nam 2200289 a 45 001 957231
005 20110630
008 110630s2007 ||||||||||||||||| ||eng d
020 $a 9780549038405
035 $a (UMI)AAI3265137
035 $a AAI3265137
040 $a UMI $c UMI
100 1 $a Zhang, Yuting. $3 1280584
245 1 0 $a Do newer prescription drugs pay for themselves? Searching for appropriate empirical methodologies.
300 $a 101 p.
500 $a Adviser: Richard G. Frank.
500 $a Source: Dissertation Abstracts International, Volume: 68-05, Section: A, page: 2090.
502 $a Thesis (Ph.D.)--Harvard University, 2007.
520 $a Newer and more expensive drugs account for a large proportion of the recent rapid growth of prescription drug spending. However, if use of newer drugs can reduce spending on other medical services, it may save total healthcare costs (the "cost-saving effect"). Aggregate-level evidence of the cost-saving effect is supported by two well-cited studies conducted by Frank Lichtenberg. He argued that in the aggregate, using new drugs reduces total healthcare costs. In Paper 1, I reassess this evidence and conclude the original findings are not maintained under plausible alternative approaches. Thus, we do not have robust evidence of the aggregate cost-saving effect.
520 $a Furthermore, wide variations in safety, efficacy and costs exist across drugs and diseases. In Paper 2, I investigate the cost-saving effect in one clinical area---atypical antipsychotic agents compared with traditional mood stabilizers as long-term treatment for bipolar disorder. Using commercial insurance claims data from 1998-2001, I test the hypothesis through several econometric methods, including a propensity-score matching, interrupted time series, differencing strategies, and an instrumental variables approach. Each method can identify the cost-saving effect in a different way, but together they can serve as checks for robustness. I consistently find that the new medication does not reduce non-drug medical spending for patients with bipolar disorder.
520 $a Nevertheless, the cost-saving effect is plausible both theoretically and empirically. Cost-saving evidence is often shared across jurisdictions and used to guide decisions regarding the adoption and reimbursement of new drugs. However, variations in healthcare rationing policies may complicate the generalizability of such cost-saving evidence. In Paper 3, I propose an economic approach to generalizability of evidence on cost-saving effects for new prescription drugs across health systems with different rationing schemes. I note that the cost-saving effect depends on a new drug's effect on the relative prices of drug and non-drug medical inputs to health outcomes, as well as the substitutability between the two inputs. I also show that quantity constraints on non-drug treatments mainly decrease the cost-saving effect; and for some special cases, overall budgetary rationing reduces the cost-saving effect as well. This paper therefore demonstrates the importance of considering rationing schemes when applying cost-saving evidence across countries.
590 $a School code: 0084.
650 4 $a Economics, General. $3 1017424
690 $a 0501
710 2 $a Harvard University. $3 528741
773 0 $t Dissertation Abstracts International $g 68-05A.
790 $a 0084
790 1 0 $a Frank, Richard G., $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3265137